Small Food-Derived Peptides Inhibit Both ACE and DPP-4: Blood Pressure and Blood Sugar Benefits
Specific short peptides (GP, RGDS, SY) showed dual inhibition of ACE and DPP-4 enzymes, with molecular docking revealing binding mechanisms for combined blood pressure and blood sugar benefits.
Quick Facts
What This Study Found
Short food-derived peptides (GP, RGDS, SY) demonstrated dual ACE and DPP-4 inhibitory activity, with molecular docking characterizing their binding mechanisms.
Key Numbers
ACE was purified 3,575-fold. Enzyme molecular weight: two bands at ~60 kDa and ~70 kDa. Vmax: 96.15 µmol/min. Three peptides tested: GP (2 residues), RGDS (4 residues), SDGRG (5 residues).
How They Did This
In vitro enzyme inhibition assays for ACE and DPP-4. Molecular docking to characterize peptide-enzyme binding interactions. Tested three specific short peptides.
Why This Research Matters
Finding single peptides that inhibit both ACE (blood pressure) and DPP-4 (preserves GLP-1 for blood sugar) from food sources suggests dietary approaches to combined cardiometabolic health.
The Bigger Picture
Pharmaceutical companies sell separate ACE inhibitor and DPP-4 inhibitor drugs. Finding that simple food peptides can do both simultaneously suggests nature has already optimized multi-target metabolic protection — accessible through diet.
What This Study Doesn't Tell Us
In vitro study. Inhibitory potency much lower than pharmaceutical drugs. Peptide stability during digestion and absorption is unknown. Clinical significance of food-level inhibition is uncertain.
Questions This Raises
- ?Are the ACE/DPP-4 inhibition levels from food peptides clinically meaningful?
- ?Do these peptides survive digestion intact to reach their enzyme targets?
- ?Could concentrated food peptide supplements provide meaningful dual inhibition?
Trust & Context
- Key Stat:
- Dual enzyme inhibition Simple food peptides GP, RGDS, and SY inhibit both blood pressure (ACE) and blood sugar (DPP-4) enzymes
- Evidence Grade:
- Preliminary evidence: in vitro enzyme inhibition with molecular modeling. No in vivo or clinical data.
- Study Age:
- Published in 2024. Advances understanding of multi-target food-derived bioactive peptides.
- Original Title:
- Exploration of inhibitor effect of Gly-Pro (GP), Arg-Gly-Asp-Ser (RGDS) and Ser-Asp-Gly-Arg-Gly (SDGRG) bioactive peptides on angiotensin-converting enzyme activity purified from human serum.
- Published In:
- Journal of biomolecular structure & dynamics, 43(10), 4901-4909 (2025)
- Authors:
- Adanas, Resul, Turkoglu, Vedat
- Database ID:
- RPEP-09769
Evidence Hierarchy
Frequently Asked Questions
Can food peptides act like blood pressure and diabetes drugs?
These small peptides inhibit the same enzymes as ACE inhibitors and DPP-4 inhibitors. However, the effect is much milder than pharmaceutical drugs. Think of it as gentle, dietary-level metabolic support rather than drug-equivalent treatment.
Which foods contain these peptides?
GP, RGDS, and SY are released when protein-rich foods are digested. They are found in dairy, meat, fish, and legume protein digests. Regular protein consumption provides exposure to these and many other bioactive peptides.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09769APA
Adanas, Resul; Turkoglu, Vedat. (2025). Exploration of inhibitor effect of Gly-Pro (GP), Arg-Gly-Asp-Ser (RGDS) and Ser-Asp-Gly-Arg-Gly (SDGRG) bioactive peptides on angiotensin-converting enzyme activity purified from human serum.. Journal of biomolecular structure & dynamics, 43(10), 4901-4909. https://doi.org/10.1080/07391102.2024.2306195
MLA
Adanas, Resul, et al. "Exploration of inhibitor effect of Gly-Pro (GP), Arg-Gly-Asp-Ser (RGDS) and Ser-Asp-Gly-Arg-Gly (SDGRG) bioactive peptides on angiotensin-converting enzyme activity purified from human serum.." Journal of biomolecular structure & dynamics, 2025. https://doi.org/10.1080/07391102.2024.2306195
RethinkPeptides
RethinkPeptides Research Database. "Exploration of inhibitor effect of Gly-Pro (GP), Arg-Gly-Asp..." RPEP-09769. Retrieved from https://rethinkpeptides.com/research/adanas-2025-exploration-of-inhibitor-effect
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.